Elanco Animal Health (ELAN) Scheduled to Post Earnings on Thursday

Elanco Animal Health (NYSE:ELAN) will post its quarterly earnings results before the market opens on Thursday, November 7th. Analysts expect Elanco Animal Health to post earnings of $0.12 per share for the quarter. Individual interested in participating in the company’s earnings conference call can do so using this link.

Elanco Animal Health (NYSE:ELAN) last posted its quarterly earnings data on Thursday, August 8th. The company reported $0.30 EPS for the quarter, beating the consensus estimate of $0.24 by $0.06. The firm had revenue of $1.18 billion during the quarter, compared to analyst estimates of $1.15 billion. Elanco Animal Health had a negative net margin of 27.94% and a positive return on equity of 7.29%. The company’s revenue for the quarter was up 12.0% on a year-over-year basis. During the same quarter last year, the business posted $0.18 EPS. On average, analysts expect Elanco Animal Health to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Elanco Animal Health Trading Up 2.1 %

NYSE:ELAN opened at $12.77 on Thursday. The company has a debt-to-equity ratio of 0.92, a quick ratio of 1.75 and a current ratio of 2.93. The firm has a market cap of $6.31 billion, a price-to-earnings ratio of -4.82, a price-to-earnings-growth ratio of 1.32 and a beta of 1.40. Elanco Animal Health has a 52 week low of $8.59 and a 52 week high of $18.80. The firm has a 50-day moving average price of $14.19 and a two-hundred day moving average price of $14.75.

Analyst Ratings Changes

ELAN has been the subject of several analyst reports. Morgan Stanley lowered shares of Elanco Animal Health from an “overweight” rating to an “equal weight” rating and decreased their price objective for the company from $17.00 to $15.00 in a research note on Thursday, September 19th. Stifel Nicolaus reissued a “buy” rating and set a $20.00 target price on shares of Elanco Animal Health in a research report on Thursday, September 19th. Finally, Barclays reduced their target price on shares of Elanco Animal Health from $22.00 to $19.00 and set an “overweight” rating for the company in a research report on Monday. One research analyst has rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $17.00.

Insider Buying and Selling

In other news, Director Michael J. Harrington bought 3,500 shares of the stock in a transaction on Thursday, August 22nd. The shares were acquired at an average cost of $14.85 per share, for a total transaction of $51,975.00. Following the purchase, the director now directly owns 81,094 shares of the company’s stock, valued at $1,204,245.90. This trade represents a 0.00 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In related news, CEO Jeffrey N. Simmons acquired 100,000 shares of the stock in a transaction dated Monday, August 12th. The shares were purchased at an average price of $13.01 per share, for a total transaction of $1,301,000.00. Following the transaction, the chief executive officer now owns 145,000 shares in the company, valued at $1,886,450. This represents a 200.00 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Michael J. Harrington acquired 3,500 shares of the stock in a transaction dated Thursday, August 22nd. The shares were bought at an average price of $14.85 per share, for a total transaction of $51,975.00. Following the transaction, the director now owns 81,094 shares in the company, valued at approximately $1,204,245.90. This represents a 0.00 % increase in their position. The disclosure for this purchase can be found here. 0.57% of the stock is owned by insiders.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.